Compare DexCom, Inc. (DXCM) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs D Wave Quantum Inc — how do they compare? DexCom, Inc. trades at $90.66 (market cap $33.79B), while D Wave Quantum Inc trades at $20.71 (market cap $7.53B). The key difference: DexCom, Inc. is far larger — about 4.5× D Wave Quantum Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | QBTS | |
|---|---|---|
Market Cap | $33.79B | $7.53B |
Sector | Health | Technology |
52-Week High | $89.53 | $44.78 |
52-Week Low | $54.84 | $12.98 |
Enterprise Value | $33.24B | $7.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
D-Wave Quantum (QBTS) trades at $20.57, up 1.86% on the day, with a bearish technical signal despite unanimous analyst buy ratings. The stock exhibits extreme valuation metrics, including a P/S ratio of 583.84, while fundamentals show deep losses with a net income margin of -2001.59% in 2026. Recent Q2 2026 earnings missed revenue estimates but highlighted a 1120% surge in bookings, per Barrons on August 6, 2026.
The outlook hinges on commercial adoption of quantum computing, offering speculative upside with a consensus price target of $38.29, but high execution risks and cash burn pose significant threats to shareholder value amid volatile sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
